Last reviewed · How we verify
Matching placebo to glimepiride
This is a placebo formulation designed to match the appearance and characteristics of glimepiride for use in clinical trials.
This is a placebo formulation designed to match the appearance and characteristics of glimepiride for use in clinical trials. Used for Clinical trial comparator for glimepiride efficacy and safety studies.
At a glance
| Generic name | Matching placebo to glimepiride |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Matching placebos are inert formulations created to be indistinguishable from the active drug in blinded clinical trials. In this case, the placebo is manufactured to match glimepiride (a sulfonylurea) in appearance, taste, and other sensory properties to maintain blinding and reduce bias in trial participants and investigators.
Approved indications
- Clinical trial comparator for glimepiride efficacy and safety studies
Common side effects
Key clinical trials
- Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (PHASE3)
- Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes (PHASE3)
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) (PHASE3)
- SGLT2 Inhibition and Left Ventricular Mass (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012) (PHASE3)
- Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema (PHASE4)
- Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo to glimepiride CI brief — competitive landscape report
- Matching placebo to glimepiride updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI